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Matrix -carboxyglutamic acid protein (MGP) is a
member of the vitamin K-dependent protein family with
unique structural and physical properties. MGP has
been shown to be an inhibitor of arterial wall and
cartilage calcification. One inhibitory mechanism is
thought to be binding of bone morphogenetic protein-2.
Binding has been shown to be dependent upon the vita-
min K-dependent -carboxylation modification of MGP.
Since MGP is an insoluble matrix protein, this work has
focused on intracellular processing and transport of
MGP to become an extracellular binding protein for
bone morphogenetic protein-2. Human vascular smooth
muscle cells (VSMCs) were infected with an adenovirus
carrying the MGP construct, which produced non--car-
boxylated MGP and fully -carboxylated MGP. Both
forms of MGP were found in the cytosolic and microso-
mal fractions obtained from the cells by differential cen-
trifugation. The crude microsomal fraction was shown
to contain an additional, more acidic Ser-phosphoryl-
ated form of MGP believed to be the product of Golgi
casein kinase. The data suggest that phosphorylation of
MGP dictates different transport routes for MGP in
VSMCs. A proteomic approach failed to identify a larger
soluble precursor of MGP or an intracellular carrier
protein for MGP. Evidence is presented for a receptor-
mediated uptake mechanism for fetuin by cultured hu-
man VSMCs. Fetuin, shown by mass spectrometry not to
contain MGP, was found to be recognized by anti-MGP
antibodies. Fetuin uptake and secretion by proliferating
and differentiating cells at sites of calcification in the
arterial wall may represent an additional protective
mechanism against arterial calcification.
Formation of bone outside the skeleton (ectopic calcification)
has been recognized for 100 years, but we still have no clear
picture of the events that lead to this pathological condition
and the mechanism(s) that opposes onset of the pathology (1).
However, findings in mice deleted of the gene for a 14-kDa
vitamin K-dependent protein, matrix -carboxyglutamic acid
(Gla)1 protein (MGP), have provided new insight into the pro-
tective mechanism (2). Mice lacking the MGP gene develop
severe calcification of arteries and cartilage, suggesting that
MGP is an important inhibitor of ectopic calcification. This
function of MGP has been shown to be dependent upon the
vitamin K modification of the protein, a modification that con-
verts Glu residues in the protein to Gla calcium-binding resi-
dues (3).
Several hypotheses have been launched about mechanisms
by which MGP may work as a calcification inhibitor (1). We
demonstrated by ligand blotting that a binding interaction
exists between MGP and bone morphogenetic protein-2
(BMP-2) (4), a potent growth factor (5) that transforms undif-
ferentiated cells and subpopulations of vascular smooth muscle
cells (VSMCs) into bone-forming cells (6–8). In support of this
finding are 1) the demonstration by Zebboudj et al. (9) of a
complex between MGP and BMP-2 in cell culture medium from
MGP- and BMP-2-producing cells and 2) observations that the
activities of growth factors are often regulated by specific bind-
ing proteins through formation of protein complexes (10). Com-
plexes between BMP-2 and its soluble binding protein noggin
are known to be formed (11). On the other hand, MGP is
extremely insoluble in physiological solutions (12), which poses
the question of whether soluble complexes between MGP and
BMP-2 are being formed.
All precursors of vitamin K-dependent proteins are equipped
with a propeptide that is the site recognized by the vitamin
K-dependent -carboxylase for post-translational -carboxyla-
tion of the precursors (13). The N-terminal propeptide is nor-
mally released in the trans-Golgi apparatus before the precur-
sors become mature proteins (14). MGP is unique among the
members of the vitamin K-dependent protein family by having
the propeptide as part of the mature protein sequence (15). It is
possible that this unusual design of the protein gives MGP
properties that are not shared by the other members of the
vitamin K-dependent protein family, which include poor solu-
bility of MGP. The unique properties of MGP have hindered an
understanding of the intracellular processing and intracellular
transport of MGP to become an extracellular binding protein
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for BMP-2. A main goal of this work has been to understand the
intracellular processing and intracellular transport of MGP.
In contrast to MGP, the intracellular processing and intra-
cellular transport of BMP-2 have been studied extensively.
BMP-2 is synthesized as a 60-kDa precursor that is processed
in the secretory pathway to a small 18-kDa monomer. Two
monomers associate to form the active homodimer of the
growth factor (16). In contrast to processing of BMP-2, process-
ing of MGP includes its post-translational vitamin K-depend-
ent modification step in the endoplasmic reticulum. If the vi-
tamin K-dependent -carboxylation system is inhibited by
coumarin anticoagulant drugs (17) or the cell is deficient in
vitamin K (17), MGP may escape this modification step, and a
non--carboxylated form of MGP is produced (17).
The physical properties of fully -carboxylated MGP (Gla-
MGP) are quite different from those of non--carboxylated
MGP (Glu-MGP) in that Gla-MGP undergoes a conformational
change upon Ca2 binding (18). We have shown that this
conformational change is necessary for formation of the
MGPBMP-2 complex (4, 19), and Price et al. (20) have shown
that the fully -carboxylated protein, but not the non--carbox-
ylated protein, is carried in plasma by fetuin, suggesting that
the vitamin K modification of MGP is also essential for fetuin
binding. Furthermore, the majority of MGP proteins produced
in calcified lesions in the arterial wall appear as non--carbox-
ylated proteins that are inactive as binding proteins for BMP-2
(4), a finding that may reflect the inability of MGP to neutralize
the growth factor activity of BMP-2 at the site of pathology. The
processing and transport of the non--carboxylated form of
MGP are also poorly understood. Therefore, to understand the
MGP/BMP-2 system as a regulatory system of ectopic calcifi-
cation, it is imperative that we understand the cellular proc-
essing and transport of both forms of MGP.
VSMCs are believed to be the source of the MGP/BMP-2
system in the arterial wall (1, 9). In support of this hypothesis
is the recent demonstration in transgenic mice that Gla-MGP
produced in the vessel wall, and not systemic MGP, inhibits
arterial calcification (21). To study the cellular processing and
transport of Gla-MGP and Glu-MGP, we have used in this work
a primary culture of human VSMCs infected with an adenovi-
rus carrying the MGP construct. Overproduction of MGP by the
infected cells exceeded the capacity of the -carboxylation sys-
tem, and the cells produced a mixture of Gla-MGP and Glu-
MGP, allowing us to follow both forms of MGP in the cell. Both
forms of MGP, but not BMP-2, were found in the cytosolic
fraction obtained by subcellular fractionation of the cell homo-
genate. However, an additional, more acidic form of MGP was
found in the microsomal fraction. This additional form of MGP
was identified as the phosphoserine-modified form of MGP (22).
Fetuin was identified in both the cytosolic and microsomal
fractions. An endocytotic mechanism for fetuin uptake by the
cultured VSMCs is demonstrated. Furthermore, fetuin is
shown to harbor one or more epitopes that are recognized by
anti-MGP antibodies. This finding raises concerns about anti-
body-based assays used to quantify MGP in serum and tissue
extracts.
EXPERIMENTAL PROCEDURES
Preparation of an Adenovirus-MGP Construct—Adenovirus carrying
the coding cDNA of human MGP (adenovirus-MGP) was constructed by
site-specific bacterial transposition using the Transpose-Ad adenoviral
system (QBIOgene, Montreal, Canada). The coding region of the human
MGP cDNA (nucleotides 13–349, GenBankTM/EBI accession number
M58549) was obtained by PCR amplification of plasmid HTM1-296
from a human trabecular meshwork library (23) using high proof Taq
polymerase and primers 5-TGCAGGACGAAACCATGAAG-3 (for-
ward) and 5-TTCCCTCAGTCTCATTTGGC-3 (reverse). These prim-
ers were designed to contain KpnI and XbaI sites at their 5-ends,
respectively. The amplified insert was digested with KpnI/XbaI, puri-
fied, and cloned into a KpnI/XbaI-predigested pCR259 transfer vector
(pWX1, QBIOgene) under the transcriptional control of the cytomega-
lovirus promoter-enhancer. Upon sequencing confirmation, pWX1 was
transfected into Transpose-Ad294-competent Escherichia coli cells and
then transposed into the Ad294 plasmid, disrupting the lacZ gene.
High titer viral stocks were obtained by propagation in 293 cells
and purification by CsCl density centrifugation as described (24, 25)
Purified viruses were titered by spectrophotometric reading at A260
and stored in aliquots at 80 °C. The absence of contaminant wild-
type viruses was tested in each stock by PCR amplification with
E1A-specific primers 5-TCGAAGAGGTACTGGCTGAT-3 and 5-
TGACAAGACCTGCAACCGTG-3.
Infection of VSMCs with the Adenovirus-MGP Construct—Human
VSMCs (cc2571, Cambrex, Boston, MA) were cultured in SmGM-2
(Cambrex). At 70% confluency, cells were infected with the adenovirus-
MGP construct (multiplicity of infection of 20) and harvested 48 h after
infection. All cultures contained 10 g of vitamin K1 (Sigma)/ml of
medium. For collection of proteins secreted from the cells, cells were
washed with phosphate-buffered saline (PBS) and cultured for an ad-
ditional 16 h in serum-free SmBM (basal medium; catalog no. CC- 3177;
Cambrex). Proteins in the serum-free medium were concentrated in a
Centritrap concentrator with a 3.5-kDa cutoff.
Biotin Labeling of Fetuin—Ten mg of fetuin (molecular biology
grade) was dissolved in 1 ml of PBS. A 20-fold molar excess of EZ-Link
sulfosuccinimidobiotin was added to the fetuin solution, and the mix-
ture was reacted for 30 min at room temperature in the dark on a
rotating shaker. The reaction mixture was gel-filtrated on Sephadex
G-25 in PBS, and the void volume fraction containing biotin-conjugated
fetuin was collected. The biotin-conjugated fetuin was dialyzed against
PBS overnight at 4 °C and sterile-filtrated before added to the cell
culture medium.
Immunohistochemistry—VSMCs cultured in SmGM-2 were depleted
of endogenous fetuin by incubating the cells for 15 min at 37 °C in
serum-free SmBM as described by Lorenzo et al. (26). Fetuin binding to
the VSMC membrane was investigated by incubating depleted cells
with biotin-labeled fetuin (50 g/ml) in serum-free medium for 30 min
at 4 °C (26). Cells were washed with cold PBS and fixed for 10 min in 4%
paraformaldehyde. For competition studies, depleted cells were incu-
bated for 30 min at 4 °C in serum-free medium containing a 100-fold
excess of unlabeled fetuin over biotin-labeled fetuin. For uptake studies,
cells incubated for 30 min at 4 °C in the presence of 5 g/ml biotin-
labeled fetuin were exposed to serum-free medium at 37 °C for an
additional 30 min before being fixed in paraformaldehyde (26). For
fluorescent staining, fixed cells were incubated at room temperature for
30 min with biotin-specific monoclonal antibodies (1:100 dilution), fol-
lowed by incubation with rhodamine-labeled donkey anti-mouse IgG
(1:200 dilution) for 30 min at room temperature. Rhodamine epifluo-
rescence images were obtained using a Zeiss Axioskop equipped with a
digital camera and Axovision imaging software. Final images were
processed using Adobe Photoshop Version 7.0.1. Images of rhodamine
epifluorescence were also obtained by confocal microscopy. A Zeiss
Model 510 laser scanning confocal microscope equipped with a 40
water immersion objective was used. The optical slice thickness was 2.1
m for each image.
Cell Disruption and Subcellular Fractionation—Cells were washed
with cold PBS, and the cell lysate was prepared using modified
radioimmune precipitation assay (RIPA) buffer (50 mM Tris, 1% Non-
idet P-40, 0.25% deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, pH 7.4) containing the protease inhib-
itors aprotinin, leupeptin, and pepstatin (1 g/ml each) as recom-
mended by Upstate Biotechnology, Inc. (Lake Placid, NY). Subcellu-
lar fractionation was carried out as described previously (27) with
some modifications. Cells were washed with cold PBS and disrupted
by sonication in isotonic buffer containing 25 mM imidazole, 250 mM
sucrose, 10 g/ml Sigma protease inhibitor mixture for use with
mammalian cells and tissues, 5 g/ml orthovanadate, and 10 g/ml
NaF, pH 7.5. Cell disruption was carried out on ice in a Fisher
Scientific Sonic Dismembrator (Model 100) at setting 4. Twenty
pulses of 2-s duration were used. The protein concentration was 8
mg/ml. The sonicate was centrifuged at 10,000  g for 10 min to
remove cell debris. A microsomal pellet was obtained by subjecting
the supernatant to centrifugation at 229,000  g for 60 min in a
Ti-70.1 rotor (Beckman Instruments). The microsomal pellet and the
supernatant (cytosolic fraction) were stored frozen at 85 °C until
used in the experiments.
Electrophoresis and Western Blotting—Prior to SDS-PAGE, proteins
in cell microsomes were dissolved in 250 mM phosphate, 0.5 M KCl, 20%
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glycerol, and 0.75% CHAPS, pH 7.85, containing 10 l/ml Sigma pro-
tease inhibitor mixture and subsequently precipitated with cold ace-
tone (20 °C) by mixing 1 part protein solution with 5 parts acetone.
Cytosolic proteins and cell proteins extracted with RIPA buffer were
also precipitated with acetone as described above. The mixtures were
left overnight at 20 °C, and precipitated proteins were harvested by
centrifugation. The precipitated proteins were washed consecutively
with 5 ml of cold 10% trichloroacetic acid (4 °C) and 5 ml (v/v) of
ice-cold ether/ethanol (20 °C). The protein pellets from the ether/
ethanol washes were dried by N2 aspiration. For two-dimensional
SDS-PAGE, the dried proteins were dissolved in 8 M urea, 2%
CHAPS, 50 mM dithiothreitol, and 2% pH 3–10 ampholyte and ab-
sorbed onto Bio-Rad pH 3–10 gradient strips overnight according to
the instruction manual for the Protean isoelectric focusing cell (Bio-
Rad). SDS-PAGE in the second dimension was carried out on Crite-
rion 8–16% gradient gels (Bio-Rad) also according to the Bio-Rad
instruction manual. One-dimensional SDS-PAGE was carried out on
Criterion 8–16% gradient gels by dissolving the dried cell proteins in
SDS-PAGE running buffer containing 5% mercaptoethanol. Gels
were stained with Coomassie Brilliant Blue. Western blotting was
carried out as described (28) after transfer of proteins to polyvinyli-
dene difluoride membranes.
Immunoprecipitation—Affinity-purified polyclonal or monoclonal an-
tibodies were added to cell extracts in RIPA buffer and left overnight at
4 °C on a rotating shaker. Immune complexes were captured with
protein A-Dynabeads (Dynal Biotech) and washed on a magnetic rack
as described in the instruction manual for Dynabeads. Proteins were
released from the beads with 8 M urea, 2% CHAPS, 50 mM dithiothre-
itol, and 2% pH 3–10 ampholyte and absorbed onto Bio-Rad pH 3–10
isoelectric focusing gradient strips overnight. For one-dimensional
SDS-PAGE, proteins were released from the beads by boiling the beads
in SDS-PAGE running buffer containing 5% mercaptoethanol.
Assays—-Carboxylase activity was assayed as described for VSMCs
(27) as 14CO2 incorporation into the synthetic peptide FLEEL. The
reaction was triggered by adding chemically reduced vitamin K1H2 (100
g/ml) to the assay mixture.
Mass Spectrometry—In-gel digestion of Coomassie Blue-stained pro-
teins on SDS-polyacrylamide gels was carried out with trypsin, and
sequence analysis was performed at the Harvard Microchemistry Fa-
cility (Cambridge, MA) by microcapillary reverse-phase HPLC/nano-
spray tandem mass spectrometry (MS/MS) on a Finnigan LCQ DECA
XP quadrupole ion trap spectrometer.
Materials—The anti-MGP N-terminal peptide antibodies were raised
in rabbits against a synthetic peptide covering residues 6–37 of the
human MGP sequence (19). These antibodies recognize MGP independ-
ently of the -carboxylation status of the MGP protein (19). The anti-
Glu-MGP and anti-Gla-MGP antibodies were raised in rabbits against
synthetic peptides covering the Gla region of MGP. Synthesis of these
peptides, antibody production, and purification of conformation-specific
antibodies against the Gla region of MGP have been described (4). The
anti-Glu-MGP and anti-Gla-MGP antibodies recognize the non--car-
boxylated and fully -carboxylated forms of MGP, respectively (19).
Goat anti-human BMP-2 polyclonal antibodies were prepared as de-
scribed (4). All of the anti-MGP peptide antibodies prepared by our
laboratory and also the anti-BMP-2 antibodies (4) were affinity-
purified by our laboratory and stored frozen at 85 °C in 50% glyc-
erol/water as described (4, 19). A monoclonal antibody made against
human MGP epitope 3–15 (N-terminal residues 3–15 of the human
MGP sequence) was purchased from VitaK Inc. (University of Maas-
tricht, Maastricht, The Netherlands). Affinity-purified rabbit anti-
phosphoserine polyclonal antibodies (Poly-Z-PS1) were from Zymed
Laboratories Inc.. Mouse anti-biotin, horseradish peroxidase-
conjugated goat anti-rabbit IgG (H  L), horseradish peroxidase-
conjugated goat anti-mouse IgG (H  L), and TRITC-conjugated
donkey anti-mouse IgG (H  L) antibodies were from Jackson Immu-
noResearch Laboratories, Inc. (West Grove, PA). Mouse anti-human
Golgi apparatus monoclonal antibodies (clone AE-6) were from Cal-
biochem. Anti-bovine fetuin polyclonal antibodies (IgG fraction) were
from Acris (Hiddenhausen, Germany). These antibodies were affin-
ity-purified on a bovine fetuin-Sepharose affinity resin prepared by
our laboratory and stored frozen at 85 °C in 50% glycerol/water.
Bovine fetuin (molecular biology grade) was from USBiological
(Swampscott, MA). A2-hs-glycoprotein from human plasma and fetuin
from fetal calf serum were from Sigma. EZ-Link sulfosuccinimidyl
6-(biotinamido)hexanoate was from Pierce. Centriprep 3000 NMWL
centrifugal filter units were from Millipore Corp. All other chemicals
were chemical grade or better.
RESULTS
Adenovirus-MGP Infection of VSMCs—VSMCs infected with
the adenovirus-MGP construct resulted in overexpression of
MGP. Fig. 1 shows Western blots with the anti-MGP N-termi-
nal peptide antibodies of proteins present in a RIPA buffer
extract (RIPA Ext.) of control cells (Cont.) and infected cells
(Ad-MGP) and in the pellets of cell debris left over after RIPA
buffer extraction (PELLET) of control and infected cells. A
14-kDa protein recognized by the antibodies appeared both in
the RIPA buffer extract of infected cells (lane B) and in the
proteins in the infected cells that were not soluble in RIPA
buffer (lane D). An immune reaction with a 60-kDa protein was
also seen. VSMCs are known to synthesize MGP (29). We could
detect MGP in the control cells when a longer exposure time
was used for imaging Western blots for chemiluminescence
(data not shown).
Searching for an Intracellular MGP Carrier Protein(s) or
Precursor—The unique properties of MGP and the poor solu-
bility of the protein prompted a search for the cellular mecha-
nism(s) by which MGP is transported intracellularly and re-
leased from the cell. Initially, we considered two possible
mechanisms. 1) Although the mRNA for MGP does predict
translation of a protein 23 kDa (20), we did not exclude the
possibility that a larger soluble precursor of MGP could be
made and processed to a smaller protein before secretion from
the cell; and 2) MGP could be carried through the cell attached
to a carrier protein to assure solubility of MGP.
VSMCs infected with the adenovirus-MGP construct were
extracted with RIPA buffer, and the extracted proteins were
separated by two-dimensional SDS-PAGE (Fig. 2A). Proteins
on identical two-dimensional gels were transferred to polyvi-
nylidene difluoride membranes for Western blotting with the
FIG. 1. Human VSMCs infected with the adenovirus-MGP
construct. Uninfected (control (Cont.)) and infected (Ad-MGP)
VSMCs were harvested, and cell extracts were made with RIPA
buffer (RIPA Ext.) as described under “Experimental Procedures.”
Cell debris not soluble in RIPA buffer (PELLET) was collected by
centrifugation. Proteins from control and infected cells were sub-
jected to SDS-PAGE and transferred to a polyvinylidene difluoride
membrane for Western blotting with the affinity-purified anti-MGP
N-terminal peptide antibodies (MGP N-term.abs.) prepared by our
laboratory (see “Experimental Procedures”).
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anti-MGP N-terminal peptide antibodies (Fig. 2B) and the anti-
BMP-2 antibodies (Fig. 2C). As shown in Fig. 2B, the anti-MGP
N-terminal peptide antibodies recognized a 60-kDa protein
spot (MGP like protein, 60 kDa), several proteins of intermedi-
ate size, the basic 14-kDa non--carboxylated form of MGP
(Glu-MGP), and the more acidic fully -carboxylated form (Gla-
MGP). The positions of Glu-MGP and Gla-MGP on the two-
dimensional gel were determined by Western blotting with the
anti-Glu-MGP and anti-Gla-MGP peptide antibodies, respec-
tively (data not shown). Fig. 2C shows the Western blot ob-
tained with the anti-BMP-2 antibodies. Consistent with the
known processing events of BMP-2 (16), several immunoreac-
tive proteins were identified in the RIPA buffer extract along
with the basic 18-kDa monomer of the growth factor. These
data show that MGP and BMP-2 were produced by the cultured
human VSMCs.
Identification of the 60-kDa MGP-like Protein—The Coomas-
sie Blue-stained protein spot labeled MGP like protein, 60 kDa
in Fig. 2A was excised from the two-dimensional gel and sub-
jected to in-gel digestion with trypsin, and peptides were ana-
lyzed by MS/MS for protein identification. The identities of five
proteins present in the excised spot are shown in Table I. No
tryptic peptides from the MGP sequence could be identified.
This negative finding strongly suggested that none of the pro-
teins identified in the Coomassie Blue-stained MGP like pro-
tein,60 kDa spot could be a MGP precursor or a protein carry-
ing the MGP protein. The most abundant protein present in the
spot was bovine fetuin. The characteristic shape of the spot is
also typical of the appearance of bovine fetuin on two-dimen-
sional SDS-polyacrylamide gels (Die Fetuin Hompage,
132.130.13.185/Fetuin-HP/ebene31.html).
Cellular Uptake of Fetuin—The conclusive identification of
bovine fetuin in the RIPA buffer extract of cultured human
VSMCs showed that the fetuin protein came from fetal bovine
serum in the cell culture medium. Active uptake mechanisms
for fetuin have been documented in embryonic, undifferenti-
ated, and tumor cells (31, 33), but have never been shown to
exist in primary cultures of VSMCs. Therefore, we set out to
determine whether our primary culture of human VSMCs
could internalize fetuin by endocytosis.
To investigate the mechanism, VSMCs were incubated first
with biotin-labeled bovine fetuin at 4 °C, which maintains re-
TABLE I
Tryptic in-gel digestion of proteins and their identification by
microcapillary reverse-phase HPLC/nanospray MS/MS
The Coomassie Blue-stained spot labeled MGP like protein, 60 kDa in
Fig. 2 was excised from the gel and subjected to analysis. Proteins
identified in the gel piece are shown.




Bovine fetuin NP_776409 28
Type II transmembrane protein p63 NP_006816 15







FIG. 2. Two-dimensional SDS-PAGE and Western blotting of proteins in RIPA buffer extracts of VSMCs infected with the
adenovirus-MGP construct. Human VSMCs were cultured, infected with the virus, and harvested as described under “Experimental Proce-
dures.” A, Coomassie Blue-stained two-dimensional SDS-polyacrylamide gel of proteins present in a RIPA buffer extract of infected cells; B and C,
Western blots of the same proteins with affinity-purified anti-MGP N-terminal peptide and anti-BMP-2 antibodies, respectively. The positions of
Glu-MGP and Gla-MGP on the gel (A) and on the membrane (B) were determined with the anti-Glu-MGP and anti-Gla-MGP antibodies as
described under “Experimental Procedures” (not shown). IF, isoelectric focusing.
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ceptor binding but prevents endocytosis (34). Next, the cells
were incubated at 37 °C, which triggers endocytosis of receptor-
bound fetuin (35). As shown in Fig. 3A, cells incubated with
biotin-labeled fetuin at 4 °C showed intense rhodamine fluo-
rescent staining of biotin-labeled fetuin attached to the cell
membrane, but only faint staining of the interior of the
paraformaldehyde-fixed cells could be seen. In a parallel exper-
iment, the VSMCs were incubated at 4 °C with biotin-labeled
fetuin in the presence of a 100-fold excess of unlabeled bovine
fetuin. As shown in Fig. 3B, excess unlabeled fetuin signifi-
cantly prevented rhodamine fluorescent staining of the cell
membrane, suggesting competition between unlabeled and bi-
otin-labeled fetuin for binding sites on the VSMC membrane.
Fig. 3C shows rhodamine staining when the cells were first
incubated for 30 min at 4 °C with biotin-labeled fetuin, followed
by a 30-min incubation at 37 °C. Clearly, raising the tempera-
ture allowed biotin-labeled fetuin to be internalized, and the
protein then appeared in intracellular organelles with little
staining of the cell membrane. The control experiment shown
in Fig. 3D was identical to the experiment shown in Fig. 3C
except that the experiment was carried out in the absence of
biotin-labeled fetuin. No noticeable background staining was
seen. Omitting the anti-biotin antibody from the experiments
resulted in no fluorescent staining (data not shown). We also
imaged this experiment using confocal microscopy. The confo-
cal image of biotin-labeled fetuin attached to the cell membrane
at 4 °C is shown in Fig. 4A. Incubation with biotin-labeled
fetuin at 4 °C followed by incubation at 37 °C resulted in the
image shown in Fig. 4B. Again, biotin-labeled fetuin appeared
in intracellular organelles, consistent with endocytosis of the
protein. The confocal image provided conclusive evidence for an
intracellular localization of the rhodamine-stained organelles.
Recognition of Fetuin by Anti-MGP Peptide Antibodies—The
finding that our anti-MGP N-terminal peptide antibodies rec-
ognized the MGP like protein,60 kDa spot shown on the two-
dimensional SDS-polyacrylamide gel in Fig. 2A suggested that
the anti-MGP N-terminal peptide antibodies recognized bovine
fetuin. This was indeed confirmed by Western blotting of com-
mercially available purified fetuin. As shown in Fig. 5A, our
affinity-purified anti-bovine fetuin antibodies recognized bo-
vine and human fetuin, reflecting the high degree of sequence
homology (70%) between the two proteins. Fig. 5B shows that
our affinity-purified anti-MGP N-terminal peptide antibodies
recognized human and bovine fetuin purchased from two dif-
ferent suppliers (Bovine (Sigma) and Bovine* (USBiological)).
We also purchased an anti-MGP monoclonal antibody (VitaK
Inc.) made against an N-terminal peptide containing residues
3–15 of the MGP sequence. As shown in Fig. 5C, the VitaK
monoclonal peptide antibodies also recognized fetuin. The
horseradish peroxidase-conjugated secondary antibodies used
for immunodetection did not recognize fetuin. Since Price et al.
(20) have shown that serum fetuin carries MGP noncovalently,
we overloaded a two-dimensional SDS-polyacrylamide gel with
bovine fetuin purchased from Sigma (see legend to Fig. 5) to
search for the 14-kDa mature form of MGP. The stained image
of the two-dimensional gel is shown in Fig. 6. A variety of
different proteins were shown to be present in the commercial
fetuin preparation. However, no stained protein spot with a
molecular mass of 14 kDa was seen. The arrow in Fig. 6
indicates where purified mature MGP would have appeared on
the two-dimensional SDS-polyacrylamide gel (4). The absence
of MGP on the gel supports the MS/MS data and the conclusion
that the anti-MGP N-terminal peptide antibodies recognize one
or more epitopes present on the fetuin protein.
Fetuin Secreted from VSMCs Is Recognized by Anti-MGP
N-terminal Antibodies—VSMCs cultured in SmGM-2 were
rinsed with PBS, and culture was continued for 16 h in serum-
free SmBM. Proteins in the serum-free media from uninfected
cells (Fig. 7, Control) and infected cells (Fig. 7, Infected) were
subjected to SDS-PAGE, followed by Western blotting with the
anti-MGP N-terminal peptide antibodies. As shown in Fig. 7,
the antibodies recognized a 60-kDa protein in the media from
control and infected cells. The protein was identified as fetuin.
No protein with a molecular mass corresponding to MGP (14
kDa) was seen. The result is consistent with secretion of inter-
nalized fetuin by VSMCs (26) and adds further support to the
finding that the anti-MGP N-terminal peptide antibodies rec-
ognize fetuin.
FIG. 3. Biotin-labeled fetuin binding and uptake by cultured
human VSMCs. VSMCs were depleted of endogenous fetuin and incu-
bated at 4 or 37 °C in serum-free medium containing biotin-labeled
fetuin or biotin-labeled fetuin plus fetuin. Incubations, paraformalde-
hyde fixation, and rhodamine fluorescent staining are described under
“Experimental Procedures.” A, cells incubated with biotin-labeled fe-
tuin for 30 min at 4 °C; B, cells incubated for 30 min at 4 °C in the
presence of a 100-fold excess of unlabeled fetuin over biotin-labeled
fetuin; C, cells incubated with biotin-labeled fetuin for 30 min at 4 °C,
followed by incubation at 37 °C for an additional 30 min; D, same
experiment as in C, except that biotin-labeled fetuin was absent. Rho-
damine epifluorescence images were obtained using a Zeiss Axioskop
equipped with a digital camera and Axovision imaging software. Final
images were processed using Adobe Photoshop Version 7.0.1. Scale
bar  25 m.
FIG. 4. Confocal microscopy of biotin-labeled fetuin binding
and uptake by cultured human VSMCs. The experiments were
identical to those described in the legend to Fig. 3. A, cells incubated
with biotin-labeled fetuin for 30 min at 4 °C; B, cells incubated with
biotin-labeled fetuin for 30 min at 4 °C, followed by incubation at 37 °C
for an additional 30 min. Images of rhodamine epifluorescence were
obtained using a Zeiss Model 510 laser scanning confocal microscope
equipped with and 40 water immersion objective. The optical slice
thickness was 2.1 m for each image. Scale bar  25 m.
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Fetuin Internalized by VSMCs Is Not a Carrier of Intracel-
lular MGP but Is Recognized by MGP Conformation-specific
Antibodies—Since serum fetuin has been shown to carry mature
Gla-MGP noncovalently (20), we investigated whether fetuin en-
docytosed by the cultured VSMCs could carry MGP intracellu-
larly in a similar way. A RIPA buffer extract of infected cells was
incubated with affinity-purified anti-fetuin antibodies, and im-
mune complexes were isolated with protein A-Dynabeads as de-
scribed under “Experimental Procedures.” Fig. 8 shows a West-
ern blot with the anti-MGP-Gla peptide antibodies of captured
immune complexes subjected to two-dimensional SDS-PAGE. To
our surprise, a strong immune reaction of fetuin was seen with
affinity-purified conformation-specific anti-Gla-MGP antibodies
(19), but no 14-kDa immunoreactive band was visible on the blot.
This finding eliminated the possibility of co-immunoprecipitation
of a noncovalently linked complex between mature MGP and
fetuin. On the other hand, the anti-Glu-MGP antibodies did not
recognize fetuin on the two-dimensional SDS-PAGE blot (data
not shown). We could conclude from these results that fetuin
internalized by the VSMCs is not a cellular carrier of MGP but
share epitopes recognized by antibodies raised against MGP syn-
thetic peptides.
MGP in Subcellular Fractions of VSMCs—Since a RIPA
buffer extract of cells will contain proteins from the cytosol as
well as from cellular compartments and organelles, we carried
out subcellular fractionation of cell homogenates from virus-
infected cells in isotonic buffer to more specifically localize
MGP in VSMCs. The microsomal fraction was shown to contain
endoplasmic reticulum vesicles, as -carboxylase activity could
be measured. However, the fraction also contained vesicles
derived from the Golgi apparatus, as anti-Golgi marker anti-
bodies (see “Experimental Procedures”) recognized a 50-kDa
Golgi resident protein (data not shown). Fig. 9 (A and C) shows
Coomassie Blue-stained polyvinylidene difluoride membranes
containing cytosolic proteins and proteins from the microsomal
fraction, respectively, after their transfer to the membranes for
immunoblotting. Fig. 9 (B and D) shows Western blots of the
proteins in Fig. 9A (cytosolic) and Fig. 9D (microsomal) with
anti-fetuin antibodies. Thus, fetuin could be identified both in
the cytosolic and microsomal fractions. Fig. 10 (A and B) shows
Western blots of the 14-kDa forms of MGP appearing in the
cytosolic and microsomal fractions, respectively. Glu-MGP and
Gla-MGP were identified in both fractions, but the microsomal
fraction (Fig. 10B) contained an additional, more acidic form of
Gla-MGP. As shown in Fig. 10C, anti-phosphor-Ser antibodies
FIG. 5. Anti-MGP N-terminal peptide antibodies recognize
fetuin. Commercially available purified fetuin from human and bo-
vine sera was subjected to SDS-PAGE and Western blotting with
affinity-purified anti-bovine fetuin antibodies (ab; A), affinity-puri-
fied anti-MGP N-terminal peptide antibodies (B), and monoclonal
peptide antibodies prepared against the N-terminal part of human
MGP (C) (for details, see “Experimental Procedures”). Bovine and
Bovine* represent serum fetuin from two different suppliers (see
“Experimental Procedures”).
FIG. 6. Two-dimensional SDS-PAGE of purified serum fetuin.
Purified serum fetuin from Sigma (catalog no. F 3004) was subjected to
two-dimensional SDS-PAGE as described under “Experimental Proce-
dures.” Shown is a Coomassie Blue-stained Criterion 8–16% gradient
gel used in the second dimension. The gel was overloaded with protein.
IF, isoelectric focusing.
FIG. 7. Cultured VSMCs secrete fetuin, but not detectable
amounts of MGP, into the cell medium. Cultured human VSMCs
were exposed to serum-free medium for 16 h for collection of secreted
proteins. Proteins were concentrated on a 3.5-kDa cutoff filter and
subjected to SDS-PAGE and Western blotting with affinity-purified
anti-MGP N-terminal peptide antibodies. Infected and Control lanes
contain proteins from adenovirus-MGP-infected and uninfected
VSMCs, respectively. The protein recognized by the antibodies was
identified as fetuin. St., standards.
FIG. 8. Intracellular fetuin is not a carrier of intracellular
MGP but is recognized by MGP conformation-specific antibod-
ies. VSMCs infected with the adenovirus-MGP construct were ex-
tracted with RIPA buffer, and the extract was used for immunoprecipi-
tation of endocytosed fetuin and coprecipitating proteins. Immune
complexes were captured on protein A-Dynabeads and subjected to
two-dimensional SDS-PAGE and Western blotting as described under
“Experimental Procedures.” The two-dimensional blot was developed
with the anti-Gla-MGP antibodies, which recognized fetuin (see ar-
rows), but the 14-kDa MGP protein was not detected on the blot. IF,
isoelectric focusing.
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identified the more acidic form of MGP as the phospho-Ser-
modified form of MGP. No phosphorylated forms of MGP were
found in the cytosolic fraction. BMP-2 could also not be identi-
fied in the cytosolic fraction.
DISCUSSION
This work is the first attempt to understand the intracellular
processing and intracellular transport of the vitamin K-de-
pendent protein MGP to become an extracellular matrix pro-
tein capable of forming a complex with the potent bone-promot-
ing growth factor BMP-2. The cellular processing of the other
members of the vitamin K-dependent protein family, except for
two newly discovered transmembrane proteins (37, 38), has
been studied extensively. These water-soluble proteins are
known to follow the secretory pathway, which includes the
endoplasmic reticulum and the Golgi compartments, for their
exit from the cell. MGP, as it is purified from bone or cartilage,
is a highly insoluble protein. Poor solubility has also been
shown to be a property of MGP made by chemical synthesis
(39). If MGP should leave the ribosome as a larger soluble
precursor, this means that elongation of the polypeptide must
have extended through the UGA stop codon in the mRNA
sequence, which has been shown to occur with selenocysteine-
containing proteins (40). Although the mRNA for MGP (30)
does not predict synthesis of a larger precursor, we still decided
to use a proteomic approach for identification of all MGP-like
proteins that possibly could be a MGP precursor or a protein
carrying the smaller MGP protein. We searched for such pro-
teins in RIPA buffer extracts of adenovirus-MGP-infected hu-
man VSMCs. Our anti-MGP N-terminal peptide antibodies
recognized a 60-kDa protein and several intermediate sized
proteins in addition to the 14-kDa non--carboxylated (Glu-
MGP) and fully -carboxylated (Gla-MGP) forms of MGP. Sur-
prisingly, mass spectrometry conclusively showed that the 60-
kDa protein does not contain any sequences that could be
attributed to MGP. This conclusion was based on two independ-
ent analyses of the MS/MS data. The dominant protein present
in the 60-kDa immunoreactive spot was identified as bovine
fetuin. The intermediate sized proteins were difficult to isolate
from the gel by excision (see Fig. 1), and these spots were not
analyzed by MS/MS. We have shown that fetuin could be in-
ternalized by the cultured human VSMCs and secreted from
these cells when surrounded by a medium deficient in fetuin.
Our data are consistent with the presence of a receptor-medi-
ated uptake mechanism, a mechanism shown to exist in em-
bryonic and proliferating cells, but not in resting differentiated
cells (32). Serum fetuin carries calcium phosphate (41) and has
been shown to play a major role in preventing calcium phos-
phate precipitation from serum and deposition of the salt in
extrahepatic tissues (42). Indeed, arterial calcification has been
shown to be inversely correlated with the serum concentration
of fetuin (43). Our demonstration of an uptake mechanism for
serum fetuin by proliferating human VSMCs and its secretion
by the cells could reflect a protective mechanism against calci-
fication at pathological sites in the vessel wall. At such sites in
atherosclerotic disease and Monkeberg’s disease, VSMCs are
know to proliferate and differentiate (29). Fetuin uptake and
secretion by cells in calcifying lesions may contribute to pro-
tection against pathological calcification. The extent of this
protective mechanism by fetuin appears to be less than the
protective mechanism exerted by MGP (2), as fetuin-deficient
mice develop only minor calcified lesions (41).
Fetuin is synthesized by the liver (44) but is found as a major
FIG. 9. MGP and fetuin in subcellular fractions from adenovirus-MGP-infected VSMCs. Infected cells were disrupted in isotonic buffer
and subjected to subcellular fraction by differential centrifugation as described under “Experimental Procedures.” A and C, Coomassie Blue-stained
proteins in the cytosolic and microsomal fractions, respectively; B and D, Western blots with anti-fetuin antibodies of the proteins shown in A and
C, respectively. The positions on the membranes of proteins that reacted with the anti-Glu-MGP and anti-Gla-MGP antibodies are indicated. IF,
isoelectric focusing.
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protein in bone matrix (45). Price et al. (20) have identified a
calcium phosphatefetuin complex in serum that carries Gla-
MGP. The fetuin complex is believed to be formed in bone and
has been demonstrated to release MGP when subjected to
SDS-PAGE. Since free MGP has never been identified as a
protein in serum (4), the fetuin complex could have been the
source of MGP when measured in plasma and serum by anti-
body-based detection methods (46). We purchased serum fetuin
from independent suppliers and were unable to find the 14-kDa
MGP protein associated with either product. The reasons for
the discrepancies between the data presented by Price et al.
(20) and the results shown in this work are unclear. Further-
more, we have shown that anti-peptide antibodies raised
against the N terminus and the Gla region of MGP recognized
the 60-kDa fetuin protein. A homology search failed to reveal
any sequence homology between the two proteins. Since
MS/MS analyses eliminated the presence of MGP in the fetuin
protein that was recognized by these antibodies, it appears that
fetuin harbors false epitopes that mimic epitopes on MGP.
Although antibodies are generally accurate and specific in their
antigen detection, they can find epitopes similar to the desired
epitope on other structures. Indeed, it is not an uncommon
finding that antibodies cross-react with antigens other than the
ones that originally elicited them. Our finding raises questions
about the specificity of immunological assays that have been
used to quantify MGP in serum and tissue extracts.
Immunoprecipitation of fetuin from a RIPA buffer extract of
infected VSMCs showed that internalized fetuin is not an in-
tracellular carrier of MGP. However, Glu-MGP and Gla-MGP
were detected in the cytosolic fraction, which also harbored
fetuin. BMP-2 was not found in the cytosolic fraction, in agree-
ment with its known confinement to organelles of the secretory
pathway (16). Earlier electron microscopy studies carried out
by our laboratory on cartilage chondrocytes also showed a
cytosolic location of MGP (47). Cytosolic MGP appears to be
associated with vesicular or membrane-bound structures (47).
Since cytosolic MGP must exit from the secretory pathway
intracellularly or is taken up by endocytosis by an unknown
mechanism, our data suggest that the highly insoluble MGP
protein is carried through the cytosol packed in vesicles. These
vesicles may be precursors of matrix vesicles known to initiate
bone formation in cartilage (48).
The microsomal fraction, which was also shown to contain
vesicles derived from the Golgi apparatus, contained a third,
more acidic form of MGP. This acidic form could not be detected
in the cytosolic fraction. The acidic form was identified as the
Ser-phosphorylated form of MGP. Price et al. (22) have shown
that the motif in MGP recognized for Ser phosphorylation is
Ser-X-Glu. Procino et al. (49) have shown that Ser phosphoryl-
ation of aquaporin-2 at its Ser-X-Glu motif is carried out by
Golgi casein kinase, a membrane kinase located in the Golgi
apparatus (50). Phosphorylation of aquaporin-2 is essential for
its insertion into the plasma membrane. Non-phosphorylated
aquaporin-2 exits the Golgi apparatus in vesicles that appear
in the cytosol. The analogy to intracellular sorting of MGP, as
our work indicates, is striking. We propose that MGP, phos-
phorylated by Golgi casein kinase in the Golgi apparatus, exits
VSMCs via the secretory pathway. Dephosphorylated MGP or
MGP that escapes phosphorylation is released, as is aqua-
porin-2, from the Golgi apparatus in vesicles that appear in the
cytosol. Several studies have shown that protein kinases and
phosphatases control sorting of proteins within the Golgi ap-
paratus/endosomal system (18, 36). To understand Ser phos-
phorylation as a sorting signal for MGP and the relevance of
the signal for MGP function, we are currently conducting a
detailed study of this system in our laboratory.
In none of the experiments reported in this work were we
able to demonstrate a form of MGP that was soluble in the cell
medium or physiological buffers. The insoluble properties of
MGP strengthen our view of MGP as an insoluble matrix pro-
tein. Since one function of MGP as a matrix protein is to bind
BMP-2 via its vitamin K-dependent Gla region, we predict that
the N- or C-terminal part of the protein is attached to the
matrix, leaving the Gla region free for BMP-2 binding.
REFERENCES
1. Demer, L. L., and Tintut, Y. (2003) Arterioscler. Thromb. Vasc. Biol. 23,
1739–1743
2. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., and
Karsenty, G. (1997) Nature 386, 78–81
3. Price, P. A., Faus, S. A., and Williamson, M. K. (1998) Arterioscler. Thromb.
Vasc. Biol. 18, 1400–1407
4. Wallin, R., Cain, D., Hutson, S. M., Sane, D., and Loeser, R. (2000) Thromb.
Haemostasis 84, 1039–1044
5. Wozney, J. M., Kriz, R. W., Hewick, R. M., and Wang, E. A. (1988) Science 242,
1528–1543
6. Bostom, K., Watson, K. E., Stanfor, E. P., and Demer, L. L. (1995) Am. J.
Cardiol. 75, B88–B91
7. Bostrom, K., Watson, K. E., Horn, S., Wortham, C. H., and Demer, L. L. (1993)
J. Clin. Investig. 91, 1800–1809C. H.
8. Wallin, R., Wajih, N., Greenwood, G. T., and Sane, D. (2001) Med. Res. Rev. 21,
247–301
9. Zebboudj, A. F., Imura, M., and Bostrom, K. (2002) J. Biol. Chem. 277,
4388–4394
10. Annes, J. P., Chen, Y., Munger, J. S., and Rifkin, D. B. (2004) J. Cell Biol. 165,
723–734
11. Zimmerman, L. B., DeJesus-Escobar, J. M., and Harland, R. M. (1996) Cell 86,
599–606
FIG. 10. Identification of Ser-phos-
phorylated MGP. Proteins in the cyto-
solic (A) and microsomal (B) fractions
from adenovirus-MGP-infected VSMCs
were subjected to two-dimensional SDS-
PAGE for identification of the different
14-kDa forms of MGP present in the frac-
tions. A and B, Western blots developed
with affinity-purified anti-MGP N-termi-
nal peptide antibodies. The positions of
Glu-MGP and Gla-MGP on the blots are
indicated. C, proteins in the microsomal
fraction as visualized with anti-phospho-
Ser antibodies (P-Ser). The anti-phospho-
Ser antibodies recognized the most acidic
form of MGP present in the microsomal
fraction. Phosphorylated MGP was not
found among the cytosolic proteins (A).
IEF, isoelectric focusing.
Processing and Transport of MGP, BMP-2, and Fetuin by VSMCs 43059
12. Hauschka, P. V., Lian, J. B., Cole, D. E. C., and Gundberg, C. M. (1989)
Physiol. Rev. 69, 990–1047D. E. C.
13. Furie, B., and Furie, B. C. (1990) Blood 75, 1753–1762
14. Stanton, C., Taylor, R., and Wallin, R. (1991) Biochem. J. 277, 59–65
15. Price, P. A., Fraser, J. D., and Metz-Virca, G. (1987) Proc. Natl. Acad. Sci.
U. S. A. 84, 8335–8339
16. Israel, D. I., Nove, J., Kerns, K. M., Moutsatsos, I. K., and Kaufman, R. J.
(1992) Growth Factors 7, 139–150
17. Suttie, J.W. (1978) in Handbook of Lipid Research (Deluca, H. F., ed) pp.
211–277, Plenum Publishing Corp., New York
18. Simon, J. P., Ivanov, I. E., Shopsin, B., Hersh, D., Adesnik, M., and Sabatini,
D. D. (1996) J. Biol. Chem. 271, 16952–16961
19. Sweatt, A., Sane, D. C., Hutson, S. M., and Wallin, R. (2003) J. Thromb.
Haemostasis 1, 176–185
20. Price, P. A., Nguyen, T. M. T., and Williamson, M. K. (2003) J. Biol. Chem. 278,
22153–22160
21. Murshed, M., Schinke, T., McKee, M. D., and Karsenty, G. (2004) J. Cell Biol.
165, 625–630
22. Price, P. A., Rice, J. S., and Williamson, M. K. (1994) Protein Sci. 3, 822–830
23. Gonzalez, P., Epstein, D. L., and Borras, T. (2000) Investig. Ophthalmol. Vis.
Sci. 41, 3678–3693
24. Borras, T., Tamm, E. R., and Zigler, J. S., Jr. (1996) Investig. Ophthalmol. Vis.
Sci. 37, 1282–1293
25. Borras, T., Rowlette, L. L., Erzurum, S. C., and Epstein, D. L. (1999) Gene
Ther. 6, 515–524
26. Lorenzo, H. C., Geuskens, M., Macho, M., Lachkar, S., Verdiere-Sahugue, M.,
Pineiro, A., and Uriel, J. (1996) Tumor Biol. 17, 252–260
27. Wallin, R., Cain, D., and Sane, D. C. (1999) Thromb. Haemostasis 84,
1764–1767
28. Wajih, N., Sane, D. C., Hutson, S. M, and Wallin, R. (2004) J. Biol. Chem. 279,
25276–25283
29. Shanahan, C. M., Nathaniel, R. B., Salisbury, J. R., Proudfoot, D., Weissberg,
P. L., and Edmonds, M. E. (1999) Circulation 100, 2168–2176
30. Frazer, J. D., Otawara, Y., and Price, P. A. (1988) J. Biol. Chem. 263, 911–916
31. Uriel, J., Faivre-Bauman, A., Trojan, J., and Foiret, D. (1982) Neurosci. Lett.
27, 171–175
32. Villacampa, M.-J., Lampreve, F., Calvo, F., Naval, J., Pinerio, A., and Uriel, J.
(1984) Dev. Brain Res. 12, 77–82
33. Naval, J., Villacampa, M.-J., Goguel, A.-F., and Uriel, J. (1985) Proc. Natl.
Acad. Sci. U. S. A. 82, 3301–3305
34. Willingham, M. C., Hanover, J. A., Dickson, R. B., and Pastan, I. (1984) Proc.
Natl. Acad. Sci. U. S. A. 81, 175–179
35. Geuskens, M., Naval, J., and Uriel, J. (1986) J. Cell. Physiol. 128, 389–396
36. Molloy, S. S., Thomas, L., Kamibayashi, C., Mumby, M. C., and Thomas, G.
(1998) J. Cell Biol. 142, 1399–1411
37. Kulman, J. D., Harris, J. E., Haldeman, B. A., and Davie, E. A. (1997) Proc.
Natl. Acad. Sci. U. S. A. 94, 9058–9062
38. Kulman, J. V., Harris, J. E., Xie, L., and Davie, E. W. (2001) Proc. Natl. Acad.
Sci. U. S. A. 98, 1370–1375
39. Hackeng, T. M., Rosing, J., Spronk, H. M., and Vermeer, C. (2001) Protein Sci.
10, 864–870
40. Berry, M. J., Banu, L., Harney, J. W., and Larsen, P. R. (1993) EMBO J. 12,
3315–3322
41. Jahnen-Dechent, W., Schinke, T., Trindl, A., Muller-Ester, W., Sablitzky, F.,
Kaiser, S., and Blessing, M. (1997) J. Biol. Chem. 272, 31496–31503
42. Schinke, T., Amendt, C., Trindl, A., Poschke, O., Muller-Esterl, W., and
Jahnen-Dechent, W. (1996) J. Biol. Chem. 271, 20789–20796
43. Ketteler, M., Bongartz, P., Westenfeld, R., Wildberger, J. E., Mahnken A. H.,
Bohm, R., Metzger, T., Wanner, C., Jahnen-Dechent, W., and Floege, J.
(2003) Lancet 361, 827–833
44. Pedersen, K. O. (1976) Nature 154, 575–580
45. Ohnishi, T., Krakaki, N., Nakamura, O., Hirono, S., and Daikuhara, Y. (1991)
J. Biol. Chem. 266, 14636–14645
46. Jono, S., Ikari, Y., Vermeer, C., Dissel, P., Hasegawa, K., Shioi, A., Taniwaki,
H., Kizu, A., Nishizawa, Y., and Saito, S. (2004) Thromb. Haemostasis 91,
790–794
47. Loeser, R., Carlson, C., Tully, H., Gray, J., Miller, L., and Wallin, R. (1992)
Biochem. J. 282, 1–6
48. Garimalla, R., Bi, X., Camacho, N., Sipe, J. B., and Anderson, H. C. (2004)
Bone (N. Y.) 34, 961–970
49. Procino, G., Carmosino, M., Marin, O., Brunanti, A. M., Contri, A., Pinna,
L. A., Mannucci, R., Nielsen, S., Kwon, T.-H., Svelto, M., and Valenti, G.
(2003) FASEB J. 17, 1886–1888
50. Meggio, F., Boulton, A. P., Marchiori, F., Borin, G., Lennon, D. P., Calderan,
A., and Pinna, L. A. (1988) Eur. J. Biochem. 177, 281–284
Processing and Transport of MGP, BMP-2, and Fetuin by VSMCs43060
